CEPI LARISSA

Pikado BV helped with the preparation of this successful proposal to develop a human vaccine against Rift Valley fever. With support from the EU H2020 programme, the Coalition for Epidemic Preparedness Innovations (CEPI) will provide up to US$12.5 million for vaccine manufacturing, preclinical research, and a phase 1 study to assess the safety, tolerability, and immunogenicity of a single-dose vaccine candidate (RVFV-4s) against Rift Valley fever virus for use in humans.

July 2019